Noninvasive test may detect presence of dementia: new application for BIS, brain monitoring technology
Categories: medical technologyA machine that can interpret electrical brain activity via a sensor placed on the patient’s forehead, a monitoring technique known as BIS (bispectral index technology), commonly used to measure patient reaction to anesthesia during surgery, has been repurposed to determine decline of cognitive function in normal elderly people. The BIS technique has been used on more than 15.2 million surgery patients. Monitoring consciousness helps clinicians determine the amount of a drug needed to provide adequate sedation during surgery. Patients wake up with minimal side effects from the anesthesia, since the system ensures that overmedication does not occur.
OUTSMARTING VERBAL SCORES. The electroencephalogram (EEG)-based technology, known in its new application as BIS-AD, was recently described at the International Conference on Alzheimer’s Disease and Related Disorders held in Philadelphia last summer, in an abstract entitled “Baseline Assessment of EEG-BIS-AD in Longitudinal Trial Predicts Subjects Who Later Sought Pharmacological Cognitive Therapy.” Aspect Medical System’s technology has shown to be superior to other methods of determining cognitive function, such as cognitive assessment tests. It seems, after sufficient repetition of these standardized tests, such as the Mini Mental State examination (MMSE) and the Alzheimer’s disease Assessment Scale (ADAS-cog), patients improve their performance. Consequently, their scores have sometimes been shown to improve with each reiteration of a verbal test.
The BIS-AD technology, on the other hand, cannot be fooled and does not show the variable results common with verbal scores over time. The Cape Cod Memory Study conducted by Aspect Medical Systems was able to measure cognitive function accurately across three readings over a six-month period. The study was conducted to examine the potential of the technology as a predictor of mental decline in normal elderly patients. Of 205 patients in the study, four were subsequently prescribed treatment with Alzheimer’s disease medications. The baseline BIS-AD values for these four subjects were significantly lower than that of other study subjects. In fact, the BIS-AD values later increased for three subjects who were given medication for Alzheimer’s disease, correlating with improved cognitive function resulting from their medication. However, the scores continued to decrease for the remaining patient who continued to decline despite medication. Thus, findings of the Cape Cod Memory Study confirmed the notion of a learning effect associated with verbal tests used to determine cognitive function and that the accuracy of the MMSE and the ADAS-cog scores is compromised over time.
Verbal tests are further dependent upon verbal skills, knowledge of the language, and educational level. A patient unfamiliar with the language or having a low educational level might not do well on a verbal cognitive function test independent of cognitive function. Thus, determining the presence of a disease such as Alzheimer’s as well as the efficacy of medication for the disease through an independent assessment tool could prove invaluable.
OTHER SCANNERS IN THE WORKS. Researchers at the University of Pennsylvania, Division of Nuclear Medicine, have also examined a system for evaluating cognitive impairment. Using the PENN-PET (positron emission tomography) scanner, researchers were able to verify the severity of cognitive impairment in patients with different types of dementing illnesses. Their study validated a scoring system for evaluating fluorodeoxyglucose (FDG) positron emission tomographic (PET) scans that can be used to assess cognitive impairment in patients. The PENN-PET scanner was used to acquire FDG-PET scans of 106 patients with cognitive impairment (65 with Alzheimer’s disease, 16 with frontal lobe dementia, and 25 atypical cases). The imaging scores were compared with results from the MMSE and Dementia Severity Rating Scale (DSRS) written tests. The scanning scores correlated with both of the written tests.
VAST POTENTIAL. Noninvasive testing will likely be used more frequently to determine the extent or potential for cognitive decline. Now, a century after Alois Alzheimer first imaged amyloid plaques under a microscope, investigators may be able to image these plaques in the brains of live patients using PET scans and magnetic resonance imaging (MRI).
Noninvasive technology promises to surpass objective calculations of mental function and is certainly superior to postmortem examination of brain tissue to confirm the presence of Alzheimer’s disease.